VRNA

Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update

Revisiting Verona Pharmaceuticals